Uncategorized Archives - BioMedWire (BMW)

TuesdayMar 24, 2026 11:15 am

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology…

TuesdayMar 24, 2026 9:45 am

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation Proton therapy's ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary…

TuesdayMar 24, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026. At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL. Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning…

FridayMar 20, 2026 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs. The UK Medicines and Healthcare Products Regulatory Agency granted Promising Innovative Medicine designation to Soligenix’s SGX945 (dusquetide) for the treatment of Behçet’s disease. The recent designation in the United Kingdom builds on other regulatory recognitions previously granted to dusquetide. Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet…

FridayMar 20, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within this evolving scientific landscape, LIXTE Biotechnology is pursuing a strategy designed to improve the performance of existing cancer treatments. Inhibiting PP2A with LB-100 may increase tumor sensitivity to chemotherapy and radiation while also enhancing immune system activity against cancer cells. Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining immunotherapy with chemotherapy to help the immune system better recognize and attack tumors. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is…

WednesdayMar 18, 2026 11:15 am

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care. DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation. ETST is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services. Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside…

WednesdayMar 18, 2026 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix is leveraging its platform science to expand the therapeutic reach of its development programs and explore additional disease indications. The broader emphasis of Soligenix’s platform science approach is to maximize the scientific value of its research infrastructure. Medical progress has transformed the treatment of many common illnesses, yet thousands of rare diseases still lack effective therapies. Companies working at the intersection of biotechnology innovation and rare disease research are increasingly focused on addressing these gaps, including Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing and…

MondayMar 16, 2026 9:45 am

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer. LIXTE develops LB-100, a drug that enhances the effectiveness of cancer treatments, while Liora has developed a unique cancer treatment that’s believed to be more affordable, precise, and efficient than many traditional options. Together, this pair of products have incredible clinical and commercial potential, to both help the businesses succeed, while also offering better outcomes for patients suffering from cancer. LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined,…

FridayMar 13, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and GSK The company operates at the nexus of targeted cancer biology and combination therapy innovation These partnerships help underscore LIXTE’s broader strategy: enhancing established cancer treatments through its first-in-class compound LB 100 LIXTE Biotechnology Holdings (NASDAQ: LIXT) continues to promote its lead oncology asset, LB 100, through a partnership-driven model designed to accelerate development and improve scientific validation. Recently, the company announced the expansion of its ongoing clinical collaboration with the University of Texas MD Anderson Cancer Center and GSK plc to evaluate LB 100…

ThursdayMar 12, 2026 10:00 am

California Chooses to Take on Federal Government on Public Health Issues

California, led by Democratic governor Gavin Newsom, has decided to break with the federal positions on public health and has resolved to stand by policies backed by science rather than the controversial positions being taken by the federal government through its health secretary R. F. Kennedy Jr. Many see the policies being pushed by the federal administration as misinformation and politicization of matters that should entirely be based on rigorous science. For example, Kennedy has linked autism to vaccination despite the lack of solid scientific data backing such a claim. Policy decisions like changing vaccine mandates have been seen as taking the country backwards from the…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Heartbeam Inc. (NASDAQ: BEAT) Partners with Mount Sinai to Accelerate AI-ECG Development and Validation

Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach

Soligenix Inc. (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape

Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care

Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Innovation Through Platform Science and Expanding Therapeutic Pipeline

Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora’s Proton Therapy

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands LB 100 Development Through Strategic Academic and Pharma Partnerships

California Chooses to Take on Federal Government on Public Health Issues

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search